Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials

Overview

Journal Pathogens

Date 2024 Jun 26

PMID 38921800

Authors

Vaishali S Mankad

Amanda Leach

Yue Chang

Ulrika Wahlby Hamren

Alexandre Kiazand

Robert J Kubiak

Therese Takas

Tonya Villafana

Manish Shroff

Affiliations

Soon will be listed here.

Abstract

Background: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to severe RSV disease through their second RSV season. We summarize a pre-specified analysis of nirsevimab safety data from three randomized controlled trials: Phase 2b (NCT02878330; healthy infants born ≥29 to <35 weeks' gestational age [wGA]); Phase 3 MELODY (NCT03979313; healthy infants born ≥35 wGA); and Phase 2/3 MEDLEY (NCT03959488; infants with congenital heart disease [CHD] and/or chronic lung disease of prematurity [CLD] or born ≤35 wGA).

Methods: Participants (randomized 2:1) received a single intramuscular dose of nirsevimab or comparator (placebo, Phase 2b/MELODY; 5× once-monthly palivizumab, MEDLEY) before their first RSV season (recipients < 5 kg, nirsevimab 50 mg; ≥5 kg, nirsevimab 100 mg). In MEDLEY, children with CHD/CLD continued to a second RSV season: first-season nirsevimab recipients received nirsevimab 200 mg; first-season palivizumab recipients were re-randomized 1:1 to receive nirsevimab 200 mg or 5× once-monthly palivizumab.

Results: The incidence, severity, and nature of AEs were similar across treatments (nirsevimab, = 3184; placebo, = 1284; palivizumab, = 304). Most AEs were mild to moderate in severity, with ≥98% unrelated to treatment. AEs of special interest occurred infrequently (<1%): no anaphylaxis or thrombocytopenia were treatment-related, and no immune complex disease was reported. Deaths (incidence < 1.0%) were all unrelated to treatment.

Conclusions: A single dose per season of nirsevimab for the prevention of RSV disease had a favorable safety profile, irrespective of wGA or comorbidities.

Citing Articles

A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults.

Mao X, Hua X, Wu C, Ge X, Zhang J, Wu X Clin Transl Sci. 2024; 18(1):e70095.

PMID: 39736101 PMC: 11684469. DOI: 10.1111/cts.70095.

RSV vaccination as the optimal prevention strategy for older adults.

Andreoni M, Bonanni P, Gabutti G, Maggi S, Siliquini R, Ungar A Infez Med. 2024; 32(4):478-488.

PMID: 39660164 PMC: 11627484. DOI: 10.53854/liim-3204-6.

Abu-Raya B, Langley J, Lavoie P CMAJ. 2024; 196(40):E1349-E1352.

PMID: 39586606 PMC: 11588394. DOI: 10.1503/cmaj.240780-f.

Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue.

Li Q, Li H, Li Z, Wang Y MedComm (2020). 2024; 5(12):e70016.

PMID: 39575302 PMC: 11581781. DOI: 10.1002/mco2.70016.

Nirsevimab to reduce infant morbidity from respiratory syncytial virus.

Abu-Raya B, Langley J, Lavoie P CMAJ. 2024; 196(32):E1114-E1117.

PMID: 39353638 PMC: 11444692. DOI: 10.1503/cmaj.240780.

References

Chaw P, Hua L, Cunningham S, Campbell H, Mikolajczyk R, Nair H . Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infections in Children With Bronchopulmonary Dysplasia: Systematic Review and Meta-Analysis. J Infect Dis. 2019; 222(Suppl 7):S620-S627. DOI: 10.1093/infdis/jiz492. View

Zhu Q, McLellan J, Kallewaard N, Ulbrandt N, Palaszynski S, Zhang J . A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017; 9(388). DOI: 10.1126/scitranslmed.aaj1928. View

Delgado M, Coviello S, Monsalvo A, Melendi G, Hernandez J, Batalle J . Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2008; 15(1):34-41. PMC: 2987729. DOI: 10.1038/nm.1894. View

Greinacher A, Warkentin T . Platelet factor 4 triggers thrombo-inflammation by bridging innate and adaptive immunity. Int J Lab Hematol. 2023; 45 Suppl 2:11-22. DOI: 10.1111/ijlh.14075. View

Simoes E, Sondheimer H, Top Jr F, Meissner H, Welliver R, KRAMER A . Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr. 1998; 133(4):492-9. DOI: 10.1016/s0022-3476(98)70056-3. View

Wilkins D, Yuan Y, Chang Y, Aksyuk A, Nunez B, Wahlby-Hamren U . Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat Med. 2023; 29(5):1172-1179. PMC: 10202809. DOI: 10.1038/s41591-023-02316-5. View

. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics. 1997; 99(1):93-9. DOI: 10.1542/peds.99.1.93. View

Griffin M, Yuan Y, Takas T, Domachowske J, Madhi S, Manzoni P . Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020; 383(5):415-425. DOI: 10.1056/NEJMoa1913556. View

Murphy B, Walsh E . Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol. 1988; 26(8):1595-7. PMC: 266671. DOI: 10.1128/jcm.26.8.1595-1597.1988. View

10.

Yoshikawa T, Morooka M, Suga S, Niinomi Y, Kaneko T, Shinoda K . Five cases of thrombocytopenia induced by primary human herpesvirus 6 infection. Acta Paediatr Jpn. 1998; 40(3):278-81. DOI: 10.1111/j.1442-200x.1998.tb01928.x. View

11.

. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998; 102(3 Pt 1):531-7. View

12.

Mankarious S, Lee M, Fischer S, Pyun K, Ochs H, Oxelius V . The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med. 1988; 112(5):634-40. View

13.

Drysdale S, Cathie K, Flamein F, Knuf M, Collins A, Hill H . Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023; 389(26):2425-2435. DOI: 10.1056/NEJMoa2309189. View

14.

Kuo T, Aveson V . Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011; 3(5):422-30. PMC: 3225846. DOI: 10.4161/mabs.3.5.16983. View

15.

Feltes T, Sondheimer H, Tulloh R, Harris B, Jensen K, Losonsky G . A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011; 70(2):186-91. DOI: 10.1203/PDR.0b013e318220a553. View

16.

Domachowske J, Madhi S, Simoes E, Atanasova V, Cabanas F, Furuno K . Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. N Engl J Med. 2022; 386(9):892-894. DOI: 10.1056/NEJMc2112186. View

17.

Carbonell-Estrany X, Simoes E, Dagan R, Hall C, Harris B, Hultquist M . Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2009; 125(1):e35-51. DOI: 10.1542/peds.2008-1036. View

18.

Hall C, Weinberg G, Blumkin A, Edwards K, Staat M, Schultz A . Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013; 132(2):e341-8. DOI: 10.1542/peds.2013-0303. View

19.

Wegzyn C, Toh L, Notario G, Biguenet S, Unnebrink K, Park C . Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review. Infect Dis Ther. 2014; 3(2):133-58. PMC: 4269625. DOI: 10.1007/s40121-014-0046-6. View

20.

Polack F, Teng M, Collins P, Prince G, Exner M, Regele H . A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002; 196(6):859-65. PMC: 2194058. DOI: 10.1084/jem.20020781. View